| Name | Title | Contact Details |
|---|
Biodex Medical Systems, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Biodex Medical Systems, Inc. is based in Shirley, NY. You can find more information on Biodex Medical Systems, Inc. at www.biodex.com
Highmark Blue Cross Blue Shield West Virginia is a Parkersburg, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Eskaton is a nonprofit senior services provider serving Northern California`s older adults for over 50 years. Through innovative approaches to health, housing and social services, Eskaton is Transforming the Aging Experience by offering life-enriching experiences and creating a culture of purposeful living. Well-being is the very center of our philosophy, and we express our belief that Age is Beautiful by celebrating the lives of older adults throughout the Eskaton family. Certified in 2019 as “A Great Place to Work” by Fortune Magazine, Eskaton genuinely cares about the financial security, health and well-being of their staff members. In addition to competitive pay and comprehensive benefits that include a company-funded retirement program, Eskaton employees appreciate knowing their work makes a real difference—both in the community, and in the lives they touch. (129/744) Employment opportunities at Eskaton our wide-ranging, including (but not limited to) the following: • Administration • Nursing • Care-Giving • Maintenance • Dining Services • Housekeeping • Security
Parkcliffe is a Toledo, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.